House Appropriations Committee approves FY23 $2.5B increase for NIH

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

News Analysis

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”

HHS issues direct final rule to reduce reliance on animal testing

FDA has issued a direct final rule that changes the language in its regulations so that “animal testing” is no longer described as the default or defining form of “nonclinical” safety testing.

September 25, 2026

Vol.52 No.35

By Claire Marie Porter

Podcast

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

In this episode of The Cancer Letter Podcast, Fran Visco, president of the National Breast Cancer Coalition, and Jacquelyn Cobb, managing editor of The Cancer Letter, discuss the Metastatic Breast Cancer Act, bipartisan legislation that would eliminate the waiting periods for Social Security Disability Insurance and Medicare for eligible people with metastatic breast cancer.

September 23, 2026

In Brief

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.

September 18, 2026

Vol.52 No.34

In Brief

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

Researchers at VCU Massey Comprehensive Cancer Center were recently awarded a $2.5 million R01 grant from NCI. The five-year grant will allow Massey to evaluate the efficacy of TROP2 targeted antibody-drug conjugates to further enhance therapeutic benefits in both breast and pancreatic cancer care.

September 18, 2026

Vol.52 No.34

House Appropriations Committee approves FY23 $2.5B increase for NIH

YOU MAY BE INTERESTED IN

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

HHS issues direct final rule to reduce reliance on animal testing

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login